Supernus Pharm (SUPN) Tops Q1 EPS by 3c

Supernus Pharm (NASDAQ: SUPN) reported Q1 EPS of ($0.38), $0.03 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $9 million versus the consensus estimate of $9.94 million.

For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• BIG3 Basketball to go public via Graf Global merger at $290 million
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital